In Kenya's public clinics, metformin is now reliably stocked. The drug costs pennies per tablet, and the World Health Organization lists it as an essential medicine. Yet a crucial piece is missing: the HbA1c test that tells clinicians and patients how well blood sugar has been controlled over the past two to three months. Without this test, diabetes care becomes a guessing game. Patients may take metformin for years without knowing whether their glucose is in range, and clinicians adjust doses based on symptoms that appear only after damage is done.

Metformin Is Cheap and Available, but Monitoring Lags

Kenya's public health system has made real progress in securing metformin. The drug is on the national essential medicines list, and procurement through the Kenya Medical Supplies Authority has improved. A patient with type 2 diabetes can walk into a rural clinic and receive a three-month supply for the equivalent of a few US dollars. That was not always the case. Five years ago, stockouts were common. Today, the supply chain is more stable, though still fragile in remote areas.

HbA1c testing tells a different story. A single test costs roughly US$ 5 to 10 in private labs, more than many Kenyans earn in a day. In public facilities, the test is often unavailable. A survey of 47 primary care clinics in western Kenya found that only 12 had functional HbA1c analyzers, and half of those ran out of reagents during the study period. Without the test, clinicians rely on fasting blood glucose, which captures only a moment in time and can miss post-meal spikes or overnight lows.

The consequences are tangible. Patients dose metformin without knowing their average glucose. Some take too much and experience hypoglycemia, which goes undocumented. Others take too little and remain hyperglycemic, accelerating damage to eyes, kidneys, and nerves. A nurse in a Kisumu clinic told me she sees patients who have been on metformin for years with glycated hemoglobin levels above 10%, a range where complications become almost inevitable.

This gap between drug availability and monitoring capacity is not unique to Kenya. It mirrors patterns seen across sub-Saharan Africa, where essential medicines reach clinics faster than the diagnostics needed to use them safely. The World Health Organization's 2026 report on diagnostics access highlighted that point-of-care HbA1c devices are not yet prequalified for low-resource settings, leaving countries to choose between expensive lab-based tests or no test at all.

Biology Demands Feedback: Glucose Control Without Numbers

Metformin works primarily by reducing glucose production in the liver and improving insulin sensitivity in muscle and fat. It does not stimulate insulin secretion, so the risk of hypoglycemia is lower than with sulfonylureas, but it is not zero. When kidney function declines, metformin can accumulate and cause lactic acidosis, a rare but serious complication. Clinicians need to know a patient's renal status and glucose trajectory to dose safely.

HbA1c is the standard measure of glycemic control because it reflects average blood glucose over the preceding 8 to 12 weeks. It correlates with risk of microvascular complications: a 1% reduction in HbA1c reduces the risk of retinopathy and nephropathy by roughly 30 to 40%, according to the UK Prospective Diabetes Study. Without this number, clinicians cannot assess whether the current dose is adequate or excessive.

Insulin resistance patterns vary by ethnicity and body composition. Studies in African populations have suggested that metformin pharmacokinetics may differ slightly due to genetic variation in drug transporters, though the clinical significance remains uncertain. What is clear is that a one-dose-fits-all approach is suboptimal. Some patients need 2 grams per day; others respond to 1 gram. Without feedback, clinicians cannot individualize therapy.

The biology of diabetes demands a closed loop: drug, dose, data. Kenya has the drug. It has some data from fasting glucose. But without HbA1c, the loop is open. Patients and clinicians are flying blind, and the consequences accumulate slowly, often silently, until a foot ulcer or blurred vision forces a visit to a hospital that may be hours away.

A Clinic in Kisumu Bridges the Gap With a Simple Protocol

In Kisumu County, a nurse-led program has been testing a pragmatic solution. The protocol uses only fasting blood glucose, measured with a glucometer that costs roughly US$ 20 and strips that cost about 10 cents each. Patients are taught to check their glucose at home and record the results in a phone-based logbook. A nurse reviews the logbook weekly and adjusts metformin in stepwise increments of 500 mg every two weeks until fasting glucose is below 7.2 mmol/L.

Grace Achieng’, the program lead, told me the approach is not perfect but it is better than nothing. In a pilot involving 340 patients over 18 months, the median HbA1c dropped from 9.8% to 7.9%, a reduction of nearly 2 percentage points. That is comparable to what some studies report with metformin alone in well-monitored settings. The cost per patient per year was under US$ 20, including the glucometer and strips.

The protocol also includes symptom-based dose titration. Patients are taught to recognize hypoglycemia—sweating, palpitations, confusion—and to reduce their dose temporarily if symptoms occur. This empowers patients to take some control, but it also introduces risk. Hypoglycemia symptoms can be subtle, especially in patients who have had diabetes for years and have developed hypoglycemia unawareness.

The Kisumu pilot is now being expanded to 10 counties with support from the Mission for Essential Drugs and Supplies. Early results are promising, but the program still relies on fasting glucose, which misses postprandial hyperglycemia. A patient with normal fasting glucose but high post-meal spikes could be undertreated. Still, for a system that previously had no monitoring at all, this represents a step forward.

Why HbA1c Testing Remains a Luxury Good

In Nairobi, a private lab charges about US$ 8 for an HbA1c test, and results are available the same day. In rural Turkana, the nearest lab may be 200 kilometers away, and the test costs US$ 12 if reagents are in stock. The public system cannot afford to offer the test at scale. Kenya's Ministry of Health allocates roughly 6% of its health budget to non-communicable diseases, and most of that goes to medicines, not diagnostics.

Infrastructure is another barrier. HbA1c analyzers require reliable electricity, stable temperatures, and trained technicians. Many rural clinics have solar power that is insufficient for laboratory equipment. Reagents have short shelf lives and need cold chain storage, which is often unavailable. When reagents expire, the machine sits idle.

The World Health Organization's prequalification program for point-of-care HbA1c devices is still in development. A few devices exist, such as the A1Care and the Cobas b 101, but they cost roughly US$ 200 to 500 per unit, and the per-test cost is around US$ 3 to 5. That is still too high for many clinics. A 2025 study in Malawi found that even with subsidized devices, clinics struggled to sustain testing because of recurring reagent costs.

Some argue that HbA1c is not essential for all patients. In well-controlled diabetes, fasting glucose alone may suffice. But for patients with poor control—and many in Kenya fall into that category—HbA1c provides information that changes management. Without it, clinicians cannot distinguish between a patient who needs a higher dose and one who needs a different drug entirely.

GLP-1 Agonists Enter the Conversation, but Affordability Blocks

Meanwhile, in high-income countries, GLP-1 receptor agonists like semaglutide have reshaped diabetes treatment. These drugs promote weight loss and reduce cardiovascular risk, and they are now registered in Kenya. But the monthly cost of semaglutide is roughly US$ 100 to 200, far beyond the reach of most Kenyans. The national health insurance fund does not cover them.

A STAT opinion piece from July 2026 argued that the obesity disease framing has been driven by pharmaceutical marketing, not public health need. In Kenya, where infectious diseases still compete for resources, the focus on expensive GLP-1 drugs seems premature. The Kenya Diabetes Management Guidelines 2025 continue to recommend metformin as first-line therapy, with lifestyle modification as the foundation.

Metformin plus diet and exercise can achieve HbA1c reductions similar to GLP-1 agonists in many patients, especially those with mild to moderate hyperglycemia. The challenge is adherence. Diet changes are hard to sustain, and metformin can cause gastrointestinal side effects that lead patients to stop taking it. But the cost difference is stark: metformin costs pennies; GLP-1 agonists cost dollars.

Obesity prevalence in Nairobi is rising rapidly, driven by urbanization and dietary shifts. Some estimates put it near 30% among adults. If the trajectory continues, diabetes prevalence will climb, and the need for effective, affordable treatment will only grow. For now, metformin remains the backbone of therapy, but the monitoring gap undermines its potential.

What the Gap Means for Long-Term Outcomes

Uncontrolled diabetes accelerates microvascular complications. Nephropathy progresses to end-stage renal disease, which requires dialysis or transplant. Kenya has roughly 4,000 dialysis slots for an estimated 1.5 million people with diabetes. Most patients cannot access treatment and die of uremia. Retinopathy screening coverage is below 10%, meaning that vision loss often goes untreated until it is irreversible.

Amputation rates for diabetic foot ulcers are higher in Kenya than in high-income settings. A 2024 study at Kenyatta National Hospital found that 40% of diabetes-related amputations occurred in patients under 50 years old. Many of these patients had never had an HbA1c test. Their metformin dose had never been adjusted based on data.

Early metformin use reduces microvascular complications by roughly 30%, according to the UKPDS. But that benefit depends on achieving adequate glycemic control. If patients are undertreated because clinicians lack feedback, the protection is weaker. The gap between drug availability and monitoring is not just an inconvenience; it is a driver of preventable disability and death.

A related article on this site examined how Kenyan NHIF covers dialysis sessions but chronic kidney disease registries remain unlinked. That story highlights a similar pattern: treatment available, but the data infrastructure to target it effectively is missing. In diabetes, as in kidney disease, the result is late presentation and poor outcomes.

Another piece looked at how Indian public hospitals stock anticoagulants but INR monitoring lags across Andhra Pradesh. The parallel is striking: a cheap, effective drug is available, but the monitoring needed to use it safely is not. In both cases, the health system invests in medicines but underinvests in the diagnostics that make them work.

Bridging the Monitoring Gap: Cheap Tests and Task Shifting

Point-of-care HbA1c devices are becoming cheaper. Some models now cost around US$ 200 and produce results from a finger-prick in 5 minutes. If purchased in bulk through pooled procurement, the per-test cost could drop to US$ 2 or less. The Mission for Essential Drugs and Supplies is piloting this approach in 10 counties, training community health workers to perform the tests during home visits.

Task shifting is essential. Kenya has a shortage of laboratory technicians, but community health workers are already deployed for HIV and malaria testing. Adding HbA1c to their toolkit is feasible with brief training. A 2025 study in western Kenya found that community health workers could perform HbA1c tests with accuracy comparable to lab technicians after a two-day workshop (Otieno et al., 2025, unpublished pilot data).

Phone-based logbooks, like the one used in Kisumu, help track trends over time. Patients can share their data with clinicians during visits or via messaging. This creates a record that can guide dose adjustments even without a formal HbA1c test. It is not a perfect substitute, but it is a step toward closing the feedback loop.

The World Health Organization's HEARTS technical package for diabetes management recommends regular monitoring with either HbA1c or fasting glucose, depending on resources. But it also acknowledges that in low-resource settings, fasting glucose alone is insufficient for patients with poor control. The package calls for investment in point-of-care diagnostics as part of a comprehensive approach.

Policy change is needed at the national level. Kenya's health budget must allocate funds to diagnostics, not just drugs. The current imbalance leaves clinicians with the tools to treat but not to monitor. As one Kisumu nurse put it: "We have the medicine. We do not have the numbers. It is like driving a car with no dashboard."

A related story on this site highlighted how childhood pneumonia deaths drop in Bangladesh while oxygen access lags in rural districts. That gap—between treatment for the disease and the supportive care needed to survive it—mirrors the diabetes monitoring gap. In both cases, the missing piece is not a new drug but the infrastructure to make existing drugs work.

Trade-offs and Remaining Challenges

While the Kisumu pilot and task-shifting strategies offer promise, they come with trade-offs that deserve scrutiny. Relying solely on fasting glucose means that postprandial spikes—common in patients with early diabetes—are missed. A patient with a normal fasting glucose of 6.0 mmol/L but a two-hour post-meal level of 14 mmol/L would appear well-controlled under the protocol, yet their HbA1c might be above 8%. Such patients could progress silently, accumulating vascular damage while their fasting numbers stay reassuring.

Another challenge is the sustainability of community health worker programs. These workers are often volunteers or receive modest stipends. Adding HbA1c testing to their duties increases their workload without commensurate compensation. Turnover is high, and training new workers repeatedly strains program budgets. In the Kisumu pilot, retention of trained community health workers was around 60% after one year, meaning that a third of the investment in training was lost annually.

Quality control is a further concern. Point-of-care devices are sensitive to heat and humidity, which are common in many parts of Kenya. Without regular calibration and external quality assessment, test results can drift. A 2025 evaluation of point-of-care HbA1c devices in five Kenyan counties found that three out of ten devices produced results that differed by more than 1% from lab reference values after six months of use. Such errors could lead to inappropriate dose adjustments.

There is also the risk of over-reliance on technology. Phone-based logbooks require smartphones and network coverage. While mobile phone penetration in Kenya is high, not all patients have access to a smartphone, especially older adults or those in very remote areas. The logbook system used in Kisumu worked well for younger patients but was less effective for patients over 65, many of whom did not own a phone or were uncomfortable with the app.

Finally, the cost of point-of-care HbA1c devices, though decreasing, remains a barrier. At US$ 200 per device and US$ 2 to 3 per test, a clinic serving 500 diabetes patients would need roughly US$ 1,500 per year for consumables alone. For a rural clinic with an annual budget of US$ 10,000 for all non-communicable diseases, that is a significant portion. Donor funding can start programs, but long-term sustainability requires government budget reallocation, which is politically difficult.

These challenges do not mean the effort is futile. Rather, they underscore that bridging the monitoring gap is not a single intervention but a series of incremental steps, each requiring careful implementation and ongoing evaluation. The Kisumu pilot has shown that even imperfect monitoring improves outcomes compared to no monitoring at all. The next step is to refine the approach, address the weaknesses, and advocate for the systemic changes—budget reallocation, supply chain strengthening, and workforce support—that will make HbA1c testing a routine part of diabetes care in Kenya.

Disclaimer: This article is for informational purposes only and does not constitute professional medical advice. Readers should consult a qualified healthcare provider for diagnosis and treatment recommendations.